Skip to main content

ORIGINAL RESEARCH article

Front. Endocrinol.
Sec. Clinical Diabetes
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1449558
This article is part of the Research Topic Incretin-based Therapies in the Treatment of Metabolic Syndrome: Expanding Roles Beyond Weight Management View all articles

Predictive factors of response to liraglutide in patients with type 2 diabetes mellitus and metabolic syndrome

Provisionally accepted
Jinfang Song Jinfang Song 1,2*Na Li Na Li 3*Yongru Zhuang Yongru Zhuang 2*Ya Chen Ya Chen 1*Chu Zhang Chu Zhang 2*Jian Zhu Jian Zhu 1*
  • 1 Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu Province, China
  • 2 Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu Province, China
  • 3 Jiangsu Taizhou People's Hospital, Taizhou, Jiangsu Province, China

The final, formatted version of the article will be published soon.

    Background: Although liraglutide has established advantages in treating patients with type 2 diabetes mellitus (T2DM) and metabolic syndrome (MS), there are still some patients with lower responsiveness to liraglutide. The objective of the study was to identify the predictors of response to liraglutide in patients with T2DM and MS. Methods: This retrospective cohort study included patients diagnosed with T2DM and MS who received liraglutide treatment as a part of their diabetes management for a minimum of six months. The participants were stratified into two groups: responders (HbA1c reduction≄1.0% and weight loss≄3%) and non-responders. The discrepancies in baseline data between the two groups were analyzed, containing comedications, test parameters, and basic profiles. The affecting factors of response to liraglutide by Logistic regression analysis were performed, and the predictive ability of the identified factors was evaluated by plotting a receiver operating characteristic (ROC) curve. Results: A total of 417 patients with T2DM and MS were examined and followed up according to the inclusion criteria, and 206 patients completed the follow-up; 105 (50.97%) were responders and 101 (49.03%) were non-responders to liraglutide. The binary logistic regression analysis identified baseline HbA1c, baseline BMI, and the duration of T2DM as significant predictors of glycemic and weight responses to liraglutide (P <0.05). The area under the curve of the ROC for the three predictors of liraglutide response after 6 months of treatment was 0.851 (95% confidence interval: 0.793 - 0.910). Conclusion: The baseline HbA1c, baseline BMI, and duration of T2DM were shown to be predictive factors of glycemic and weight improvements in patients with T2DM and MS treated with liraglutide, and had good predictive power.

    Keywords: liraglutide, response, Predictive factors, type 2 diabetes mellitus, metabolic syndrome

    Received: 15 Jun 2024; Accepted: 17 Sep 2024.

    Copyright: © 2024 Song, Li, Zhuang, Chen, Zhang and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Jinfang Song, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu Province, China
    Na Li, Jiangsu Taizhou People's Hospital, Taizhou, 225300, Jiangsu Province, China
    Yongru Zhuang, Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, Jiangsu Province, China
    Ya Chen, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu Province, China
    Chu Zhang, Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, Jiangsu Province, China
    Jian Zhu, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.